ABSTRACT NUMBER: ESOC2026A1332 INTRODUCTION OF APP-BASED SINGLE CALL ACTIVATION INTRODUCED BY STROKE TEAM TRAINING STREAMLINES THE ACUTE STROKE CARE PROCESS AND REDUCES DOOR-TO-NEEDLE-TIMES

Abstract Background and aims Acute ischemic stroke treatment is a time-sensitive, interdisciplinary workflow demanding efficient communication and standardized protocols to ensure rapid and safe care. Smartphone applications offer the potential to enhance communication within the acute workflow. Modifying this high-risk process requires structured implementation. We aim to evaluate the impact of app-based single call activation (SCA) introduced via stroke team training (STT) on door-to-needle-times (DNT) at our comprehensive stroke center. Methods A comprehensive stroke center implemented STT prior to launching an app-based SCA using “Join” in April 2024. The neurologist alerts the stroke team (neurologists, ED nurses, radiology technicians, neuroradiologists, stroke unit nurses) via app-based SCA and conveys key information, enabling preemptive resource preparation. Weekly one-hour STT sessions, comprising briefing, simulation, and debriefing, began before app-start in clinical routine. Median DNT for patients receiving intravenous thrombolysis (IVT) was compared before (T1) and after (T2) implementing STT and SCA. Results SCA and STT were successfully integrated. N=316 SCAs were conducted in clinical routine and n=184 professionals participated in 23 STTs. Among 225 IVT-treated patients analyzed (T1: n=111; T2: n=114), median DNT decreased significantly from 27 minutes (IQR 16–46) to 19.5 minutes (IQR 14–36). Linear regression adjusted for imaging modality (CT/MRI), trichotomized NIHSS, time window (<4.5h/>4.5h), and SCA status(yes/no) identified SCA as an independent predictor of reduced DNT [β −0.187; CI: −18.769 to −0.600]. Conclusions App-based SCA implementation introduced by STT allows the stroke team to act in concert, significantly shortening DNT. Linear regression reveals SCA as an independent factor for reduced DNT. Conflict of interest TN: nothing to disclose; HW: nothing to disclose; MS: nothing to disclose; CF: nothing to disclose; IA: nothing to disclose; WP : reports grants from the German Research Foundation, LOEWE (research funding of the federal state of Hesse); royalties or licenses STROKE TEAM-Training (LAERDAL medical); payment or honoraria from LAERDAL medical, Alexion, Pfizer-BMS, Boehringer Ingelheim and AstraZeneca; support for attending meetings and/or travel from LAERDAL medical, Alexion and Pfizer-BMS; OA-F: nothing to disclose; RS: nothing to disclose; AB: nothing to disclose; JE: nothing to disclose Figure 1 - belongs to Results